184 related articles for article (PubMed ID: 8693551)
1. Secretion of CTLA4Ig by an SV40 T antigen-transformed islet cell line inhibits graft rejection against the neoantigen.
Lew AM; Brady JL; Silva A; Coligan JE; Georgiou HM
Transplantation; 1996 Jul; 62(1):83-9. PubMed ID: 8693551
[TBL] [Abstract][Full Text] [Related]
2. Additive efficacy of CTLA4Ig and OX40Ig secreted by genetically modified grafts.
Brady JL; Lew AM
Transplantation; 2000 Mar; 69(5):724-30. PubMed ID: 10755517
[TBL] [Abstract][Full Text] [Related]
3. Enhanced survival of grafts genetically endowed with the ability to block CD2 and B7.
Brady JL; Yamashita K; Lew AM
Cell Transplant; 2001; 10(2):175-81. PubMed ID: 11332632
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.
Guo Z; Wu T; Kirchhof N; Mital D; Williams JW; Azuma M; Sutherland DE; Hering BJ
Transplantation; 2001 Jun; 71(11):1656-65. PubMed ID: 11435979
[TBL] [Abstract][Full Text] [Related]
5. The effect of CD28/B7 blockade on alloreactive T and B cells after liver cell transplantation.
Reddy B; Gupta S; Chuzhin Y; Kalergis AM; Budhai L; Zhang M; Droguett G; Horwitz MS; Chowdhury JR; Nathenson SG; Davidson A
Transplantation; 2001 Mar; 71(6):801-11. PubMed ID: 11330546
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, but not CTLA4Ig, prolongs survival of fetal pig islet grafts in anti-T cell monoclonal antibody-treated NOD mice.
Koulmanda M; Kovarik J; Mandel TE
Xenotransplantation; 1998 Aug; 5(3):215-21. PubMed ID: 9741460
[TBL] [Abstract][Full Text] [Related]
7. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways.
Woodward JE; Qin L; Chavin KD; Lin J; Tono T; Ding Y; Linsley PS; Bromberg JS; Baliga P
Transplantation; 1996 Oct; 62(7):1011-8. PubMed ID: 8878397
[TBL] [Abstract][Full Text] [Related]
8. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors.
Li W; Lu L; Wang Z; Wang L; Fung JJ; Thomson AW; Qian S
Transplantation; 2001 Oct; 72(8):1423-32. PubMed ID: 11685115
[TBL] [Abstract][Full Text] [Related]
9. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2.
Sayegh MH; Akalin E; Hancock WW; Russell ME; Carpenter CB; Linsley PS; Turka LA
J Exp Med; 1995 May; 181(5):1869-74. PubMed ID: 7536798
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of CTLA4Ig secreted by transgenic fetal pancreas allografts.
Sutherland RM; Brady JL; Georgiou HM; Thomas HE; Lew AM
Transplantation; 2000 May; 69(9):1806-12. PubMed ID: 10830215
[TBL] [Abstract][Full Text] [Related]
11. CD28-B7 T-cell co-stimulatory blockade potentiates the effects of intrathymic immunomodulation in sensitized graft recipients.
Stadlbauer TH; Schaub M; Korom S; Onodera K; Sayegh MH; Kupiec-Weglinski JW
Transplantation; 1997 Dec; 64(12):1816-22. PubMed ID: 9422425
[TBL] [Abstract][Full Text] [Related]
12. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing.
Bolling SF; Lin H; Wei RQ; Turka LA
J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989
[TBL] [Abstract][Full Text] [Related]
13. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig.
Feng S; Quickel RR; Hollister-Lock J; McLeod M; Bonner-Weir S; Mulligan RC; Weir GC
Transplantation; 1999 Jun; 67(12):1607-13. PubMed ID: 10401769
[TBL] [Abstract][Full Text] [Related]
14. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion.
Lin H; Bolling SF; Linsley PS; Wei RQ; Gordon D; Thompson CB; Turka LA
J Exp Med; 1993 Nov; 178(5):1801-6. PubMed ID: 8228826
[TBL] [Abstract][Full Text] [Related]
15. Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts.
Glysing-Jensen T; Räisänen-Sokolowski A; Sayegh MH; Russell ME
Transplantation; 1997 Dec; 64(12):1641-5. PubMed ID: 9422395
[TBL] [Abstract][Full Text] [Related]
16. Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig.
Perico N; Imberti O; Bontempelli M; Remuzzi G
Kidney Int; 1995 Jan; 47(1):241-6. PubMed ID: 7731152
[TBL] [Abstract][Full Text] [Related]
17. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses.
Onodera K; Chandraker A; Schaub M; Stadlbauer TH; Korom S; Peach R; Linsley PS; Sayegh MH; Kupiec-Weglinski JW
J Immunol; 1997 Aug; 159(4):1711-7. PubMed ID: 9257832
[TBL] [Abstract][Full Text] [Related]
18. CTLA4Ig adenoviral gene transfer induces long-term islet rat allograft survival, without tolerance, after systemic but not local intragraft expression.
Laumonier T; Potiron N; Boeffard F; Chagneau C; Brouard S; Guillot C; Soulillou JP; Anegon I; Le Mauff B
Hum Gene Ther; 2003 Apr; 14(6):561-75. PubMed ID: 12718766
[TBL] [Abstract][Full Text] [Related]
19. Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion.
Kimura F; Gotoh M; Tanaka T; Luo Z; Miyazaki J; Uede T; Monden M; Miyasaka M
Diabetologia; 2002 Jun; 45(6):831-40. PubMed ID: 12107727
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.
Lenschow DJ; Ho SC; Sattar H; Rhee L; Gray G; Nabavi N; Herold KC; Bluestone JA
J Exp Med; 1995 Mar; 181(3):1145-55. PubMed ID: 7532678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
